Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company’s significant progress toward securing European patents for its SIRT6 variant, marking a major milestone. The patent, which mirrors an earlier US patent, covers the composition of matter for the SIRT6 gene variant, a discovery made alongside the University of Colombia, Rochester University, and the Albert Einstein School of Medicine. Leire explained that the SIRT6 variant was identified through research on a unique population of Jewish Ashkenazi centenarians, showing a mutation that boosts SIRT6 activity. Highlighting the gene's role in managing DNA damage and epigenomic changes, he noted, "We are in a safer position because we secure one of the very important competitive advantages over other longevity companies." Genflow plans to apply this SIRT6 gene variant to age-related conditions such as Non-Alcoholic Steato Hepatitis (NASH), sarcopenia, and glaucoma, utilising gene therapy tools to precisely target affected areas. Beyond human applications, Leire mentioned an upcoming dog study focused on life extension and nerve cell preservation in ageing dogs, with an announcement expected soon. As Genflow enters the national phase of patent preparation, Leire emphasised the process is largely bureaucratic with minimal risk. Stay tuned for updates as the company continues to advance its innovative longevity research. For more insightful interviews and updates, visit Proactive’s YouTube channel! Don’t forget to like, subscribe, and enable notifications for future content. #GenflowBiosciences #SIRT6 #LongevityResearch #DrEricLeire #BiotechNews #EuropeanPatent #GeneTherapy #Healthspan #AgingResearch #ProactiveInterviews